aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Flare Therapeutics is dedicated to innovating small molecule medicines by deciphering the biology of transcription factors. The company aims to address unmet medical needs by developing novel therapeutics that target these critical proteins. Flare focuses on creating treatments for various diseases, leveraging its unique approach to transcription factor biology.
Flare Therapeutics has made significant strides in the biotech industry, advancing its research and development efforts. The company has garnered attention for its pioneering methods and potential to transform therapeutic approaches. Notable investors include Third Rock Ventures, which supports Flare's mission to bring groundbreaking treatments to market.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Flare Therapeutics founded?
Flare Therapeutics was founded in 2021.
Where is Flare Therapeutics's headquarters located?
Flare Therapeutics's headquarters is located in Cambridge, MA, US.
When was Flare Therapeutics's last funding round?
Flare Therapeutics's most recent funding round was for $123M (USD) in March 2023.
How many employees does Flare Therapeutics have?
Flare Therapeutics has 48 employees as of Feb 4, 2024.
How much has Flare Therapeutics raised to-date?
As of July 05, 2023, Flare Therapeutics has raised a total of $205M (USD) since Mar 22, 2023.
Add Comparison
Total Raised to Date
$205M
USD
Last Update Mar 22, 2023
Last Deal Details
$123M
USD
Mar 22, 2023
Series B
Total Employees Over Time
48
As of Feb 2024
Flare Therapeutics Address
Cambridge,
Massachusetts
02138
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts